Sanford C. Bernstein set a €105.00 ($122.09) price objective on Merck KGaA (FRA:MRK) in a report published on Monday. The firm currently has a buy rating on the healthcare company’s stock.

A number of other research analysts have also weighed in on MRK. Berenberg Bank set a €104.00 ($120.93) price objective on Merck KGaA and gave the company a buy rating in a research report on Wednesday, July 4th. Societe Generale set a €88.00 ($102.33) price objective on Merck KGaA and gave the company a neutral rating in a research report on Wednesday, July 4th. Warburg Research set a €100.00 ($116.28) price objective on Merck KGaA and gave the company a neutral rating in a research report on Wednesday, September 12th. UBS Group set a €115.00 ($133.72) price objective on Merck KGaA and gave the company a buy rating in a research report on Tuesday, June 26th. Finally, Credit Suisse Group set a €85.00 ($98.84) price objective on Merck KGaA and gave the company a neutral rating in a research report on Wednesday, July 4th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of €98.71 ($114.78).

Shares of Merck KGaA stock opened at €88.10 ($102.44) on Monday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Read More: Intrinsic Value and Stock Selection

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.